Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
A phase 3 trial testing Cevostamab in multiple myeloma, now recruiting.
Overview
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma is a phase 3 interventional study registered as NCT07555938, led by Hoffmann-La Roche, and recruiting when checked on 2026-09-11. Official title: A Phase III, Randomised, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Patients With Multiple Myeloma Who Have Received One to Three Prior Lines of Therapy. Planned enrolment is 380 participants (estimated). The study started in 2026-06-23 and primary completion is expected in 2028-10-31. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialA Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study
Shares Roche / Genentech and the tag ctgov-ingest.
- TrialA Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
Shares Roche / Genentech and the tag ctgov-ingest.
- TrialRO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
Shares Roche / Genentech and the tag ctgov-ingest.
- TrialA Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma
Shares Multiple myeloma and the tag ctgov-ingest.
- TrialA Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma
Shares Multiple myeloma and the tag ctgov-ingest.
- TrialA Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Shares Multiple myeloma and the tag ctgov-ingest.
- TrialA Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Shares Multiple myeloma and the tag ctgov-ingest.
- TrialA Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Shares Multiple myeloma and the tag ctgov-ingest.